Synthetic Biologics, Inc. announced that Frank Tufaro, Ph.D., will transition from Chief Operating Officer of recently acquired VCN Biosciences (VCN) to Chief Operating Officer of Synthetic Biologics. Dr. Tufaro will be responsible for leading strategic operations and optimizing organizational functions. As part of this acquisition, Manel Cascall?, Ph.D., former CEO of VCN, was appointed as General Director of Synthetic Biologic's European Subsidiary.

Dr. Frank Tufaro is a seasoned biotech executive with over 25 years of leadership experience. Prior to VCN Biosciences, Dr. Tufaro served as the CEO and board member of DNAtrix, Inc. Prior to this, Dr. Tufaro was CEO and Co-founder of Nurel Therapeutics, Inc. Dr. Manel Cascalló was previously the CEO of VCN Biosciences. Additionally, Dr. Cascalló is a member of the Biosafety Committee at IDIBELL.